MedTrace Logo

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

NCT01299337 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2012-05-11

No results posted yet for this study

Summary

The purpose of this study is:

* To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy.
* To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment.
* To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate.
* To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).

Conditions

Interventions

DRUG

T3

Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.

Sponsors & Collaborators

Principal Investigators

  • Christopher L Sola, D.O. · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01299337 on ClinicalTrials.gov